



May 14, 2019

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **The National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Re: Your email dated May 13, 2019 seeking clarification on the captioned media report, 'Pharma stocks bleed as US states file lawsuit against generic drug firms'

We refer to your email dated May 13, 2019.

On May 10, 2019, State Attorney Generals from multiple U.S. states filed a lawsuit against 19 companies including Lupin Pharmaceuticals, Inc. (LPI), wholly owned subsidiary of the Company, alleging violation of Federal and State Antitrust laws. The States have claimed to have been injured by paying supra-competitive prices for the products they purchased or reimbursed.

We have received a copy of the lawsuit filed against the generic drug manufacturers and are reviewing details of the same. Lupin has been a key pharmaceutical player in the US and has demonstrated full commitment to compliance with all laws and ethical business practices. We are committed to maintaining high standards across our sales and marketing practices.

As the complaint has just been filed, estimate of the possible financial impact, if any, cannot be made at this time. Thus, the same did not warrant disclosure to the Stock Exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**


R. V. SATAM
COMPANY SECRETARY



LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com